Tuesday, February 9, 2010

Biotechnology News

Chemaphor Announces Agreement With Allied Biotech Corporation

July 3, 2009 · Leave a Comment 

Chemaphor Inc. (TSX VENTURE:CFR) a biotechnology research and development company, is pleased to announce it has entered into a strategic relationship with the Allied Biotech Corporation of Taiwan. With this, Chemaphor has signed a Manufacturing Development Agreement with Allied Biotech for the development, manufacture and exclusive five year supply of Chemaphor’s OxBC compound. Dr. Paul Dick, CEO of Chemaphor, said “We are very pleased to have achieved this very important milestone on the path towards the commercialization of OxBC. We believe that our relationship with Allied Biotech... [Read the full story]

Uncategorized

Biologics Dominate the Autoimmune Market but Small Molecules Still Have Some Fight Left, Says Cutting Edge Information

July 3, 2009 · Leave a Comment 

Biological drugs are the big winners in the market for autoimmune disorders. According to “Autoimmune Market Forecast to 2014,” the latest therapeutic market forecast from Cutting Edge Information, 11 of 14 drugs projected to reach blockbuster status are biologics. In fact, sales of biologics marketed for at least one autoimmune disorder topped $29 billion in 2008. In the same year, small molecules earned only $9 billion. With projected biologics sales projected to hit $55 billion in 2014, nearly all of the major pharmaceutical companies have acquired or partnered with biotechnology... [Read the full story]

Uncategorized

Biologics Dominate the Autoimmune Market but Small Molecules Still Have Some Fight Left, Says Cutting Edge Information

July 3, 2009 · Leave a Comment 

Biological drugs are the big winners in the market for autoimmune disorders. According to “Autoimmune Market Forecast to 2014,” the latest therapeutic market forecast from Cutting Edge Information, 11 of 14 drugs projected to reach blockbuster status are biologics. In fact, sales of biologics marketed for at least one autoimmune disorder topped $29 billion in 2008. In the same year, small molecules earned only $9 billion. With projected biologics sales projected to hit $55 billion in 2014, nearly all of the major pharmaceutical companies have acquired or partnered with biotechnology... [Read the full story]

Uncategorized

Biologics Dominate the Autoimmune Market but Small Molecules Still Have Some Fight Left, Says Cutting Edge Information

July 3, 2009 · Leave a Comment 

Biological drugs are the big winners in the market for autoimmune disorders. According to “Autoimmune Market Forecast to 2014,” the latest therapeutic market forecast from Cutting Edge Information, 11 of 14 drugs projected to reach blockbuster status are biologics. In fact, sales of biologics marketed for at least one autoimmune disorder topped $29 billion in 2008. In the same year, small molecules earned only $9 billion. With projected biologics sales projected to hit $55 billion in 2014, nearly all of the major pharmaceutical companies have acquired or partnered with biotechnology... [Read the full story]

Uncategorized

Biologics Dominate the Autoimmune Market but Small Molecules Still Have Some Fight Left, Says Cutting Edge Information

July 3, 2009 · Leave a Comment 

Biological drugs are the big winners in the market for autoimmune disorders. According to “Autoimmune Market Forecast to 2014,” the latest therapeutic market forecast from Cutting Edge Information, 11 of 14 drugs projected to reach blockbuster status are biologics. In fact, sales of biologics marketed for at least one autoimmune disorder topped $29 billion in 2008. In the same year, small molecules earned only $9 billion. With projected biologics sales projected to hit $55 billion in 2014, nearly all of the major pharmaceutical companies have acquired or partnered with biotechnology... [Read the full story]

Uncategorized

Biologics Dominate the Autoimmune Market but Small Molecules Still Have Some Fight Left, Says Cutting Edge Information

July 3, 2009 · Leave a Comment 

Biological drugs are the big winners in the market for autoimmune disorders. According to “Autoimmune Market Forecast to 2014,” the latest therapeutic market forecast from Cutting Edge Information, 11 of 14 drugs projected to reach blockbuster status are biologics. In fact, sales of biologics marketed for at least one autoimmune disorder topped $29 billion in 2008. In the same year, small molecules earned only $9 billion. With projected biologics sales projected to hit $55 billion in 2014, nearly all of the major pharmaceutical companies have acquired or partnered with biotechnology... [Read the full story]

Chemaphor Announces Agreement With Allied Biotech Corporation

Chemaphor Inc. (TSX VENTURE:CFR) a biotechnology research and development company, is pleased to announce it has entered into a strategic relationship with the Allied Biotech Corporation of Taiwan. With this, Chemaphor has signed a Manufacturing Development Agreement with Allied Biotech for the development, manufacture and exclusive five year supply... Read more of this article


Solarvest BioEnergy Inc. Announces Non-Brokered Private Placement

SOLARVEST BIOENERGY INC. (TSX VENTURE:SVS) (”Solarvest” or the “Company”), wishes to announce its non-brokered private placement, pursuant to which the investors will purchase from the Company up to 500,000 common shares at a price of $0.20 per share for gross proceeds of $100,000. The private placement will be entirely subscribed... Read more of this article


Syngenta and Evogene to Collaborate on Soybean Nematode Resistance

Evogene Ltd. (TASE: EVGN) today announced a collaboration with Syngenta Biotechnology, Inc. focusing on identifying plant genes related to soybean nematode resistance. Under the agreement, Syngenta will receive exclusive licensing rights to candidate genes discovered by Evogene for use in soybean. Soybean nematode is a soil parasite which attacks the... Read more of this article


Chemaphor Announces Agreement With Allied Biotech Corporation

Chemaphor Inc. (TSX VENTURE:CFR) a biotechnology research and development company,... 


Solarvest BioEnergy Inc. Announces Non-Brokered Private Placement

SOLARVEST BIOENERGY INC. (TSX VENTURE:SVS) (”Solarvest” or the “Company”),... 


Syngenta and Evogene to Collaborate on Soybean Nematode Resistance

Evogene Ltd. (TASE: EVGN) today announced a collaboration with Syngenta Biotechnology,... 


Uncategorized

Biologics Dominate the Autoimmune Market but Small Molecules Still Have Some Fight Left, Says Cutting Edge Information

Biological drugs are the big winners in the market for autoimmune disorders. According... 


More Posts From Uncategorized